Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new method of treating wounds after major trauma costing nearly £150 per dressing is no more effective in reducing surgical infection rates than a standard wound dressing priced under £2, potentially saving the NHS millions.

Op-site dressing at laparotomy wound applied immediately to the patient after surgery. © Shutterstock

Major trauma is where a patient suffers injuries to several different parts of their body at the same time or very serious injuries to just one part. Worldwide, it is the leading cause of death in people under 45 years and a significant cause of short and long-term disability. Major trauma is commonly associated with serious limb injuries such as fractured bones, but treatment of these fractures is complicated because the soft-tissues around the bone are also badly damaged. Serious wound healing complications such as deep infection are therefore common.

The type of dressing applied over the wound at the end of the operation may reduce the risk of infection. Negative pressure wound therapy (NPWT), which involves applying gentle suction to the surface of the wound as it heals, is a relatively new treatment that has provided promising early results in patients with surgical wounds associated with major trauma.

However, a new study from NDORMS finds that the use of incisional negative pressure wound therapy, compared with standard wound dressing, resulted in no significant difference in the rate of deep surgical site infection (SSI).

Each year the NHS spends between £4.5 - £5.1bn* on wound management. Because of the extra cost of suction pumps NPWT costs an average of £149.52, compared to £1.87 for standard dressings**. Exact figures on the number of NPWT dressings currently being used in the NHS is difficult to estimate, according to researchers, but millions of standard dressings are used in the NHS each year, with NPWT also being increasingly used. The researchers are due to publish a further economic analysis of the treatments later this year.

Lead author Professor Matthew Costa said: "Negative pressure wound therapy offered the prospect of reducing patients' risk of wound infection. However, we needed to be sure about this because the new dressings are more expensive than the current standard care. In the largest study of its kind we found no evidence that negative pressure dressings reduced the risk of deep infection in the surgical wound. The negative pressure dressings were very unlikely to be cost effective. This is important because the NHS spends millions of pounds on wound dressings each year. Using less costly standard treatment will mean savings for the NHS without compromising patient outcomes."

Professor Jason Madan from Warwick Medical School was the lead health economist for the WHIST trial. He said: "If the NHS stays with standard treatment, patients will be just as healthy, and the money that would have been spent on negative pressure wound therapy can be used in other ways that do improve patients' health."

The randomised clinical trial included 1548 participants each given either NPWT, or standard wound dressing, and the primary outcome measure was deep surgical site infection at 30 days. The research found no significant difference in the infection rate in the NPWT group at 5.84% and in the standard dressing group at 6.68%.

Professor Hywel Williams, Director of the NIHR Health Technology Assessment (HTA) Programme, which funded the research, said: "When most people think of research they usually think of developing new cures and tech innovations, but this valuable study shows that research into existing innovations that are being increasingly used in the NHS can be just as important."

The results of the trial have been published in the Journal of the American Medical Association (JAMA).

The trial was supported by the NIHR Oxford Biomedical Research Centre and the NIHR Clinical Research Network.

Results of the study are also being considered by the National Wound Care Strategy Programme as part of their evidence-based recommendations in developing guidelines for the use of NPWT for the NHS.

* The annual cost to the NHS of managing patients with wounds is between £4.5 billion -£5.1 billion. Guest, J. F., Ayoub, N., Mcllwraith, T., Uchegbu, I., Gerrish, A., Weidlich, D., Vowden, K. & Vowden, P. 2015. Health economic burden that wounds impose on the National Health Service in the UK. Downloaded from http://bmjopen.bmj.com/ on January 4, 2016 - Published by group.bmj.com

** NHS Supply Chain Catalogue Jan 2019 (average)

Similar stories

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.